Business · 13/09/2022Updated: 10/17/2026 · 1 min read
Merck Sharp & Dohme Corp. Withdraws Approval of VIOXX Drug Applications
Summary
The FDA is withdrawing approval of VIOXX drug applications for Merck Sharp & Dohme Corp. due to the company's voluntary request, following a hearing waiver.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →